Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan

Journal of Digestive Diseases

Volumn 14, Issue 9, 2013, Pages 474-483

  Ou, Chi Hsing ^a   Kuo, Fu Chen ^b,d   Hsu, Wen Hung ^a,c   Lu, Chien Yu ^a   Yu, Fang Jung ^a   Kuo, Chao Hung ^a   Wang, Jaw Yuan ^a   Wu, Ming Tsang ^b   Shiea, Jentaie ^e   Wu, Deng Chyang ^a,c,e   Hu, Huang Ming ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Colorectal neoplasms; Early detection of cancer; Fecal occult blood test; Qualitative research; Quantitative

Indexed keywords

GUAIAC; HEMOGLOBIN;

ADENOMATOUS POLYP; ADULT; ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER SCREENING; CANCER SIZE; CLINICAL EVALUATION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL POLYP; COLORECTAL TUMOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TAIWAN;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECAL OCCULT BLOOD TEST; QUALITATIVE RESEARCH; QUANTITATIVE;

ADENOMA; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GUAIAC; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; INDICATORS AND REAGENTS; MALE; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84881651723     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12077     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 2005; 104: 2035-2047.
4. Mandel JS, Church TR, Bond JH etal. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-1607.
5. Hardcastle JD, Chamberlain JO, Robinson MH etal. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477.
6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471.
7. Mandel JS, Bond JH, Church TR etal. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-1371.
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714.
9. Rozen P, Levi Z, Hazazi R etal. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009; 29: 450-457.
10. Nakama H, Yamamoto M, Kamijo N etal. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999; 46: 228-231.
11. Macrae FA, St John DJ, Caligiore P, Taylor LS, Legge JW. Optimal dietary conditions for hemoccult testing. Gastroenterology 1982; 82: 899-903.
12. Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11: 148-160.
13. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-658.
14. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010; 24: 479-492.
15. Vilkin A, Rozen P, Levi Z etal. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-2525.
16. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006; 12: MT27-32.
17. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
18. Winawer SJ, Zauber AG, Ho MN etal.; The National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329: 1977-1981.
19. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M; Italian Multicentre Study Group. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812-815.
20. Levin B, Lieberman DA, McFarland B etal; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-1595.
21. Rozen P, Levi Z, Hazazi R etal. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009; 29: 906-917.
22. Guittet L, Bouvier V, Mariotte N etal. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009; 100: 1230-1235.
23. Park DI, Ryu S, Kim YH etal. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-2025.
24. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-169.
25. Yoshinaga M, Motomura S, Takeda H, Yanagisawa Z, Ikeda K. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia. Am J Gastroenterol 1995; 90: 1076-1079.
26. Fattah AS, Nakama H, Kamijo N, Fujimori K, Zhang B. Colorectal adenomatous polyps detected by immunochemical occult blood screening. Hepatogastroenterology 1998; 45: 712-716.
27. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37: 398-401.
28. Terhaar sive Droste JS, Oort FA, van der Hulst RW etal. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2011; 20: 272-280.
29. Hol L, Wilschut JA, van Ballegooijen M etal. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100: 1103-1110.
30. Wilschut JA, Hol L, Dekker E etal. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011; 141: 1648-55.e1.
31. Chen LS, Liao CS, Chang SH, Lai HC, Chen TH. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007; 14: 191-199.
32. Guittet L, Bouvier V, Mariotte N etal. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56: 210-214.
33. van Rossum LG, van Rijn AF, Laheij RJ etal. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
34. Omata F, Shintani A, Isozaki M, Masuda K, Fujita Y, Fukui T. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol 2011; 23: 1036-1041.
35. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011; 104: 1779-1785.
36. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-428.
37. Segnan N. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, 1st edn. Luxembourg: EU, 2010.
38. de Wijkerslooth TR, Stoop EM, Bossuyt PM etal. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012; 107: 1570-1578.
39. Rex DK, Ahnen DJ, Baron JA etal. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-1329; quiz 1314, 1330.